eligibility_summary
Eligible: adults (≥19) with malignant lymphoma treated at Catholic Yeouido St. Mary’s or Seoul St. Mary’s between May 2009–June 2023 who received salvage chemotherapy for relapsed/refractory disease. Exclude: acute leukemia or solid cancer diagnosed during treatment.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Observational, retrospective comparison in relapsed/refractory lymphoma: Advanced immunotherapy vs conventional chemotherapy. Advanced immunotherapy includes: 1) CAR T-cell therapy—autologous, genetically engineered T cells expressing chimeric antigen receptors, mechanism: MHC-independent recognition of lymphoma antigens, potent T-cell activation and cytolytic killing. 2) Bispecific T-cell–engager antibodies—biologic IgGs that bind CD3 on T cells and a lymphoma antigen, forming an immune synapse to activate T cells and kill tumor cells. 3) Antibody-drug conjugates—monoclonal antibodies that deliver an intracellular cytotoxic payload to antigen-expressing lymphoma cells. Targets/pathways: T-cell activation via CD3, antigen-directed killing of lymphoma cells, typically B-cell antigens (e.g., CD19/CD20/CD22). Comparator: conventional chemotherapy-based regimens.